Celgene Drops GED-0301 as Crohn’s Therapy but Will Continue Testing It for Ulcerative Colitis
News
Celgene Corporation is giving up on GED-0301 as a Crohn’s disease therapy, but will continue to evaluate its ability to treat ulcerative colitis. It ended its Phase 3 REVOLVE clinical trial (NCT02596893) and ... Read more